CHA Placenta Institute, CHA University, Seoul, Republic of Korea.
Differentiation. 2012 Oct;84(3):223-31. doi: 10.1016/j.diff.2012.05.007. Epub 2012 Aug 10.
Mesenchymal stem cells (MSCs) are powerful sources for cell therapy in regenerative medicine. The capability to obtain effective stem cell-derived hepatocytes would improve cell therapy for liver diseases. Recently, various placenta-derived stem cells (PDSCs) depending on the localization of placenta have been suggested as alternative sources of stem cells are similar to bone marrow-derived MSC (BM-MSCs) and adipose-derived MSC (AD-MSCs). However, comparative studies for the potentials of the hepatogenic differentiation among various MSCs largely lacking. Therefore, we investigated to compare the potentials for hepatogenic differentiation of PDSCs with BM-MSCs, AD-MSCs, and UCB-MSCs. Several MSCs were isolated from human term placenta, adipose tissue, and umbilical cord blood and characterized isolated MSCs and BM-MSCs was performed by quantitative reverse transcription-PCR (RT-PCR) and special stains after mesodermal differentiation. The hepatogenic potential of PDSCs was compared with AD-MSCs, UCB-MSCs, and BM-MSCs using RT-PCR, PAS stain, ICG up-take assays, albumin expression, urea production, and cytokine assays. MSCs isolated from different tissues all presented similar characteristics of MSCs. However, the proliferative potential of PDSCs and the expression of hepatogenic markers in differentiated PDSCs were higher than other MSCs. Interestingly, the expression of hepatocyte growth factor (HGF) increased in PDSCs after hepatogenic differentiation. Interestingly, stem cell factor (SCF) expression in chorionic plate-derived MSCs, one of the PDSCs, was significantly higher than in the other PDSCs. Taken together, the results of the present study suggest that MSCs isolated from various adult tissues can be induced to undergo hepatogenic differentiation in vitro, and that PDSCs may have the greatest potential for hepatogenic differentiation and proliferation. Therefore, PDSCs could be used as a stem cell source for cell therapy in liver diseases.
间充质干细胞(MSCs)是再生医学中细胞治疗的强大来源。获得有效的干细胞衍生肝细胞的能力将改善肝脏疾病的细胞治疗。最近,根据胎盘的定位,各种胎盘来源的干细胞(PDSCs)已被提出作为替代干细胞的来源,类似于骨髓来源的MSC(BM-MSCs)和脂肪来源的MSC(AD-MSCs)。然而,对于各种 MSC 的肝向分化潜能的比较研究还很缺乏。因此,我们研究了比较 PDSCs 与 BM-MSCs、AD-MSCs 和 UCB-MSCs 的肝向分化潜能。从人足月胎盘、脂肪组织和脐血中分离出几种 MSC,并通过定量逆转录聚合酶链反应(RT-PCR)和中胚层分化后的特殊染色对分离的 MSC 和 BM-MSCs 进行了鉴定。通过 RT-PCR、PAS 染色、ICG 摄取试验、白蛋白表达、尿素生成和细胞因子试验,比较了 PDSCs 与 AD-MSCs、UCB-MSCs 和 BM-MSCs 的肝向潜能。从不同组织分离的 MSC 均表现出 MSC 的相似特征。然而,PDSCs 的增殖潜能和分化后的 PDSCs 中肝向标志物的表达均高于其他 MSC。有趣的是,PDSCs 中的肝细胞生长因子(HGF)表达在肝向分化后增加。有趣的是,胎盘绒毛板来源的 MSC(PDSCs 之一)中的干细胞因子(SCF)表达明显高于其他 PDSCs。总之,本研究结果表明,从各种成人组织中分离的 MSC 可在体外诱导其进行肝向分化,而 PDSCs 可能具有最大的肝向分化和增殖潜能。因此,PDSCs 可作为肝脏疾病细胞治疗的干细胞来源。